CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASES
https://doi.org/10.15789/1563-0625-2018-3-313-340
Abstract
Our understanding of anticancer immune surveillance currently serves as a basis for development of novel therapies that utilize patient’s own immune system as an anticancer agent. Previously, cancer immunotherapy mostly included non-specific immunomodulating agents, cytokines, or cancer cell-based tumor vaccines. Emerging understanding of diverse interactions between the immune system and cancer cells allows to develop novel, more effective therapeutic approaches that target only specific populations of immune cells. Recent studies focus on testing efficiency of allogenic and authologous anticancer immunity, strategies for ex vivo expansion of these cells, and approaches to increase their anticancer activity and specificity. Most recent approaches focus on re-targeting immune cells to specific tumor antigens, shifting the balance of immunosuppressive tumor microenvironment towards immune stimulation and utilizing immune cells to target tumor architecture. This review is focused on the prospects of different immuno-therapeutic strategies.
About the Authors
Yu. N. Lezhnin
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Russian Federation
Russian Federation
Research Fellow.
Moscow
A. Yu. Khristichenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Russian Federation
Russian Federation
Research Fellow.
Moscow
N. M. Ratnikova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Russian Federation
Russian Federation
Research Fellow.
MoscowYu. E. Kravchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Russian Federation
Russian Federation
PhD (Biology).
MoscowS. P. Chumakov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Russian Federation
Russian Federation
Chumakov Stepan P. - PhD (Biology).
117997, Moscow, Miklukho-Maklaya str., 16/10, Phone: 7 (915) 006-69-68
References
1. Abken H., Hombach A., Heuser C., Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res., 2001, Vol. 158, pp. 249-264.
2. Aggarwal S.,Gurney A.L. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol., 2002, Vol. 71, no. 1, pp. 1-8.
3. Aggen D.H., Chervin A.S., Schmitt T.M., Engels B., Stone J.D., Richman S.A., Piepenbrink K.H., Baker B.M., Greenberg P.D., Schreiber H., Kranz D.M. Single-chain ValphaVbeta T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther., 2012, Vol. 19, no. 4, pp. 365-374.
4. Allavena P., Signorelli M., Chieppa M., Erba E., Bianchi G., Marchesi F., Olimpio C.O., Bonardi C., Garbi A., Lissoni A., de Braud F., Jimeno J., D’Incalci M. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res., 2005, Vol. 65, no. 7, pp. 2964-2971.
5. Altenschmidt U., Klundt E., Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J. Immunol., 1997, Vol. 159, no. 11, pp. 5509-5515.
6. Avila-Arroyo S., Nunez G.S., Garcia-Fernandez L.F., Galmarini C.M. Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines. J. Breast Cancer, 2015, Vol. 18, no. 4, pp. 329-338.
7. Benson D.M., Jr., Bakan C.E., Zhang S., Collins S.M., Liang J., Srivastava S., Hofmeister C.C., Efebera Y., Andre P., Romagne F., Blery M., Bonnafous C., Zhang J., Clever D., Caligiuri M.A., Farag S.S. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood, 2011, Vol. 118, no. 24, pp. 6387-6391.
8. Blom R.A., Amacker M., Moser C., van Dijk R.M., Bonetti R., Seydoux E., Hall S.R., von Garnier C., Blank F. Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro. Nanomedicine (London, England), 2017, Vol. 13, no. 5, pp. 1725-1737.
9. Bohnenkamp H.R., Coleman J., Burchell J.M., Taylor-Papadimitriou J., Noll T. Breast carcinoma cell lysatepulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell, Immunol., 2004, Vol. 231, no. 1-2, pp. 112-125.
10. Boiardi A., Silvani A., Ruffini P.A., Rivoltini L., Parmiani G., Broggi G., Salmaggi A. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother., 1994, Vol. 39, no. 3, pp. 193-197.
11. Breckpot K., Dullaers M., Bonehill A., van Meirvenne S., Heirman C., de Greef C., van der Bruggen P., Thielemans K. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med., 2003, Vol. 5, no. 8, pp. 654-667.
12. Bridgeman J.S., Hawkins R.E., Bagley S., Blaylock M., Holland M., Gilham D.E. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol., 2010, Vol. 184, no. 12, pp. 6938-6949.
13. Brown C.E., Badie B., Barish M.E., Weng L., Ostberg J.R., Chang W.C., Naranjo A., Starr R., Wagner J., Wright C., Zhai Y., Bading J.R., Ressler J.A., Portnow J., D’Apuzzo M., Forman S.J., Jensen M.C. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res., 2015, Vol. 21, no. 18, pp. 4062-4072.
14. Calogero A., Hospers G.A., Kruse K.M., Schrier P.I., Mulder N.H., Hooijberg E., de Leij L.F. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res., 2000, Vol. 20, no. 3A, pp. 1793-1799.
15. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., Varela-Rohena A., Haines K.M., Heitjan D.F., Albelda S.M., Carroll R.G., Riley J.L., Pastan I., June C.H. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA, 2009, Vol. 106, no. 9, pp. 3360-3365.
16. Cassier P.A., Dufresne A., Blay J.Y., Fayette J. Trabectedin and its potential in the treatment of soft tissue sarcoma. Therapeutics and Clinical Risk Management, 2008, Vol. 4, no. 1, pp. 109-116.
17. Casucci M., Nicolis di Robilant B., Falcone L., Camisa B., Norelli M., Genovese P., Gentner B., Gullotta F., Ponzoni M., Bernardi M., Marcatti M., Saudemont A., Bordignon C., Savoldo B., Ciceri F., Naldini L., Dotti G., Bonini C., Bondanza A. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood, 2013, Vol. 122, no. 20, pp. 3461-3472.
18. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat. Rev. Immunol., 2001, Vol. 1, no. 1, pp. 41-49.
19. Chang G.C., Lan H.C., Juang S.H., Wu Y.C., Lee H.C., Hung Y.M., Yang H.Y., Whang-Peng J., Liu K.J. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer, 2005, Vol. 103, no. 4, pp. 763-771.
20. Chen K.H., Wada M., Pinz K.G., Liu H., Lin K.W., Jares A., Firor A.E., Shuai X., Salman H., Golightly M., Lan F., Senzel L., Leung E.L., Jiang X., Ma Y. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 2017, Vol. 31, no. 10, pp. 2151-2160.
21. Chen X., Du Y., Hu Q., Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathology, Research and Practice, 2017, Vol. 213, no. 3, pp. 245-249.
22. Chiba S., Baghdadi M., Akiba H., Yoshiyama H., Kinoshita I., Dosaka-Akita H., Fujioka Y., Ohba Y., Gorman J.V., Colgan J.D., Hirashima M., Uede T., Takaoka A., Yagita H., Jinushi M. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol., 2012, Vol. 13, no. 9, pp. 832-842.
23. Childs R.W., Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat. Rev. Drug Discov., 2015, Vol. 14, no. 7, pp. 487-498.
24. Chmielewski M., Kopecky C., Hombach A.A., Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res., 2011, Vol. 71, no. 17, pp. 5697-5706.
25. Cho D.Y., Yang W.K., Lee H.C., Hsu D.M., Lin H.L., Lin S.Z., Chen C.C., Harn H.J., Liu C.L., Lee W.Y., Ho L.H. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg., 2012, Vol. 77, no. 5-6, pp. 736-744.
26. Chu J., Deng Y., Benson D.M., He S., Hughes T., Zhang J., Peng Y., Mao H., Yi L., Ghoshal K., He X., Devine S.M., Zhang X., Caligiuri M.A., Hofmeister C.C., Yu J. CS1-specific chimeric antigen receptor (CAR)engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 2014, Vol. 28, no. 4, pp. 917-927.
27. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res., 2007, Vol. 67, no. 19, pp. 9518-9527.
28. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol., 1999, Vol. 163, no. 1, pp. 507-513.
29. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., Gastaut J.A., Pende D., Olive D., Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood, 2002, Vol. 99, no. 10, pp. 3661-3667.
30. Cubillos-Ruiz J.R., Baird J.R., Tesone A.J., Rutkowski M.R., Scarlett U.K., Camposeco-Jacobs A.L., AnadonArnillas J., Harwood N.M., Korc M., Fiering S.N., Sempere L.F., Conejo-Garcia J.R. Reprogramming tumorassociated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res., 2012, Vol. 72, no. 7, pp. 1683-1693.
31. Cubillos-Ruiz J.R., Silberman P.C., Rutkowski M.R., Chopra S., Perales-Puchalt A., Song M., Zhang S., Bettigole S.E., Gupta D., Holcomb K., Ellenson L.H., Caputo T., Lee A.H., Conejo-Garcia J.R., Glimcher L.H. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell, 2015, Vol. 161, no. 7, pp. 1527-1538.
32. D’Incalci M., Badri N., Galmarini C.M., Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br. J. Cancer, 2014, Vol. 111, no. 4, pp. 646-650.
33. Dai H., Zhang W., Li X., Han Q., Guo Y., Zhang Y., Wang Y., Wang C., Shi F., Zhang Y., Chen M., Feng K., Wang Q., Zhu H., Fu X., Li S., Han W. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology, 2015, Vol. 4, no. 11, e1027469. doi: 10.1080/2162402X.2015.1027469.
34. Davila M.L., Riviere I., Wang X., Bartido S., Park J., Curran K., Chung S.S., Stefanski J., Borquez-Ojeda O., Olszewska M., Qu J., Wasielewska T., He Q., Fink M., Shinglot H., Youssif M., Satter M., Wang Y., Hosey J., Quintanilla H., Halton E., Bernal Y., Bouhassira D.C., Arcila M.E., Gonen M., Roboz G.J., Maslak P., Douer D., Frattini M.G., Giralt S., Sadelain M., Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 2014, Vol. 6, no. 224, pp. 224ra225.
35. de Magalhaes-Silverman M., Donnenberg A., Lembersky B., Elder E., Lister J., Rybka W., Whiteside T., Ball E. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J. Immunother., 2000, Vol. 23, no. 1, pp. 154-160.
36. Dembic Z., Haas W., Weiss S., McCubrey J., Kiefer H., von Boehmer H., Steinmetz M. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature, 1986, Vol. 320, no. 6059, pp. 232-238.
37. Drent E., Groen R.W., Noort W.A., Themeli M., Lammerts van Bueren J.J., Parren P.W., Kuball J., Sebestyen Z., Yuan H., de Bruijn J., van de Donk N.W., Martens A.C., Lokhorst H.M., Mutis T. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, Vol. 101, no. 5, pp. 616-625.
38. Duong C.P., Westwood J.A., Berry L.J., Darcy P.K., Kershaw M.H. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy, 2011, Vol. 3, no. 1, pp. 33-48.
39. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, no. 2, pp. 720-724.
40. Esser R., Muller T., Stefes D., Kloess S., Seidel D., Gillies S.D., Aperlo-Iffland C., Huston J.S., Uherek C., Schonfeld K., Tonn T., Huebener N., Lode H.N., Koehl U., Wels W.S. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. Journal of Cellular and Molecular Medicine, 2012, Vol. 16, no. 3, pp. 569-581.
41. Fairweather D., Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J. Autoimmun, 2009, Vol. 33, no. 3-4, pp. 222-230.
42. Farag S.S., Caligiuri M.A. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv. Pharmacol., 2004, Vol. 51, pp. 295-318.
43. Fedorov V.D., Themeli M., Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med., 2013, Vol. 5, no. 215, pp. 215ra172.
44. Gargett T., Brown M.P. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol., 2014, Vol. 5, p. 235.
45. Gargett T., Yu W., Dotti G., Yvon E.S., Christo S.N., Hayball J.D., Lewis I.D., Brenner M.K., Brown M.P. GD2-specific CAR T Cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther., 2016, Vol. 24, no. 6, pp. 1135-1149.
46. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, Vol. 19, no. 1, pp. 71-82.
47. Geller M.A., Miller J.S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 2011, Vol. 3, no. 12, pp. 1445-1459.
48. Gill S., Tasian S.K., Ruella M., Shestova O., Li Y., Porter D.L., Carroll M., Danet-Desnoyers G., Scholler J., Grupp S.A., June C.H., Kalos M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 2014, Vol. 123, no. 15, pp. 2343-2354.
49. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., Berman T., Joyce J.A. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes and Development, 2010, Vol. 24, no. 3, pp. 241-255.
50. Grada Z., Hegde M., Byrd T., Shaffer D.R., Ghazi A., Brawley V.S., Corder A., Schonfeld K., Koch J., Dotti G., Heslop H.E., Gottschalk S., Wels W.S., Baker M.L., Ahmed N. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic. Acids, 2013, Vol. 2, e105. doi: 10.1038/mtna.2013.32.
51. Grage-Griebenow E., Flad H.D., Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol., 2001, Vol. 69, no. 1, pp. 11-20.
52. Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., Naylor S. The macrophage – a novel system to deliver gene therapy to pathological hypoxia. Gene Ther., 2000, Vol. 7, no. 3, pp. 255-262.
53. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell, 2010, Vol. 140, no. 6, pp. 883-899.
54. Gross S., Erdmann M., Haendle I., Voland S., Berger T., Schultz E., Strasser E., Dankerl P., Janka R., Schliep S., Heinzerling L., Sotlar K., Coulie P., Schuler G., Schuler-Thurner B. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight, 2017, Vol. 2, no. 8, pii: 91438. doi: 10.1172/jci.insight.91438.
55. Guedan S., Chen X., Madar A., Carpenito C., McGettigan S.E., Frigault M.J., Lee J., Posey A.D., Jr., Scholler J., Scholler N., Bonneau R., June C.H. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood, 2014, Vol. 124, no. 7, pp. 1070-1080.
56. Hammink R., Mandal S., Eggermont L.J., Nooteboom M., Willems P.H., Tel J., Rowan A.E., Figdor C.G., Blank K.G. Controlling T-cell activation with synthetic dendritic cells using the multivalency effect. ACS Omega, 2017, Vol. 2, no. 3, pp. 937-945.
57. Hao N.B., Lu M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clinical and Developmental Immunology, 2012, Vol. 2012, 948098. doi: 10.1155/2012/948098.
58. Harnack U., Johnen H., Pecher G. Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells. Anticancer Res., 2011, Vol. 31, no. 2, pp. 475-479.
59. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol., 2005, Vol. 6, no. 11, pp. 1123-1132.
60. Haso W., Lee D.W., Shah N.N., Stetler-Stevenson M., Yuan C.M., Pastan I.H., Dimitrov D.S., Morgan R.A., FitzGerald D.J., Barrett D.M., Wayne A.S., Mackall C.L., Orentas R.J. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 2013, Vol. 121, no. 7, pp. 1165-1174.
61. Hayakawa M., Hatano T., Ogawa Y., Gakiya M., Ogura H., Osawa A. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. Urol Int., 1994, Vol. 53, no. 3, pp. 117-124.
62. Hegde M., Mukherjee M., Grada Z., Pignata A., Landi D., Navai S.A., Wakefield A., Fousek K., Bielamowicz K., Chow K.K., Brawley V.S., Byrd T.T., Krebs S., Gottschalk S., Wels W.S., Baker M.L., Dotti G., Mamonkin M., Brenner M.K., Orange J.S., Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J. Clin. Invest., 2016, Vol. 126, no. 8, pp. 3036-3052.
63. Hirschowitz E.A., Foody T., Kryscio R., Dickson L., Sturgill J., Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol., 2004, Vol. 22, no. 14, pp. 2808-2815.
64. Holtl L., Rieser C., Papesh C., Ramoner R., Herold M., Klocker H., Radmayr C., Stenzl A., Bartsch G., Thurnher M. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol., 1999, Vol. 161, no. 3, pp. 777-782.
65. Hombach A., Hombach A.A., Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther., 2010, Vol. 17, no. 10, pp. 1206-1213.
66. Hombach A.A., Heiders J., Foppe M., Chmielewski M., Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology, 2012, Vol. 1, no. 4, pp. 458-466.
67. Hombach A.A., Abken H. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy, 2013, Vol. 5, no. 7, pp. 677-681.
68. Hombach A.A., Gorgens A., Chmielewski M., Murke F., Kimpel J., Giebel B., Abken H. Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol. Ther., 2016, Vol. 24, no. 8, pp. 1423-1434.
69. Houot R., Kohrt H.E., Marabelle A., Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol., 2011, Vol. 32, no. 11, pp. 510-516.
70. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 1996, Vol. 2, no. 1, pp. 52-58.
71. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., Rigatos G., Papamichail M., Perez S.A. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother., 2010, Vol. 59, no. 12, pp. 1781-1789.
72. Imai C., Mihara K., Andreansky M., Nicholson I.C., Pui C.H., Geiger T.L., Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 2004, Vol. 18, no. 4, pp. 676-684.
73. Jensen M.C., Popplewell L., Cooper L.J., DiGiusto D., Kalos M., Ostberg J.R., Forman S.J. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation, 2010, Vol. 16, no. 9, pp. 1245-1256.
74. Jiang H., Zhang W., Shang P., Zhang H., Fu W., Ye F., Zeng T., Huang H., Zhang X., Sun W., Man-Yuen Sze D., Yi Q., Hou J. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol., 2014, Vol. 8, no. 2, pp. 297-310.
75. Jiang W., Zhang J., Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy, 2008, Vol. 10, no. 3, pp. 265-274.
76. Jing X.N., Qiu B., Wang J.F., Wu Y.G., Wu J.B., Chen D.D. In vitro anti-tumor effect of human dendritic cells vaccine induced by astragalus polysacharin: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2014, Vol. 34, no. 9, pp. 1103-1107.
77. Jochems C., Hodge J.W., Fantini M., Fujii R., Morillon Y.M., 2nd, Greiner J.W., Padget M.R., Tritsch S.R., Tsang K.Y., Campbell K.S., Klingemann H., Boissel L., Rabizadeh S., Soon-Shiong P., Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget, 2016, Vol. 7, no. 52, pp. 86359-86373.
78. Johnson L.A., Scholler J., Ohkuri T., Kosaka A., Patel P.R., McGettigan S.E., Nace A.K., Dentchev T., Thekkat P., Loew A., Boesteanu A.C., Cogdill A.P., Chen T., Fraietta J.A., Kloss C.C., Posey A.D., Jr., Engels B., Singh R., Ezell T., Idamakanti N., Ramones M.H., Li N., Zhou L., Plesa G., Seykora J.T., Okada H., June C.H., Brogdon J.L., Maus M.V. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med., 2015, Vol. 7, no. 275, pp. 275ra222.
79. Kagi D., Ledermann B., Burki K., Seiler P., Odermatt B., Olsen K.J., Podack E.R., Zinkernagel R.M., Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature, 1994, Vol. 369, no. 6475, pp. 31-37.
80. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res., 2004, Vol. 64, no. 24, pp. 9160-9166.
81. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A., Roberts B.L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumorassociated antigens. J. Immunol., 1999, Vol. 163, no. 2, pp. 699-707.
82. Katz S.C., Burga R.A., McCormack E., Wang L.J., Mooring W., Point G.R., Khare P.D., Thorn M., Ma Q., Stainken B.F., Assanah E.O., Davies R., Espat N.J., Junghans R.P. Phase I Hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res., 2015, Vol. 21, no. 14, pp. 3149-3159.
83. Kenderian S.S., Ruella M., Shestova O., Klichinsky M., Aikawa V., Morrissette J.J., Scholler J., Song D., Porter D.L., Carroll M., June C.H., Gill S. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 2015, Vol. 29, no. 8, pp. 1637-1647.
84. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev., 2008, Vol. 222, pp. 129-144.
85. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 2006, Vol. 12, no. 20, Pt 1, pp. 6106-6115.
86. Khan J.A.,Yaqin S. Successful immunological treatment of gallbladder cancer in India--case report. J. Zhejiang. Univ. Sci. B., 2006, Vol. 7, no. 9, pp. 719-724.
87. Klingemann H., Boissel L., Toneguzzo F. Natural killer cells for immunotherapy – advantages of the NK-92 cell line over blood NK cells. Front. Immunol., 2016, Vol. 7, p. 91.
88. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol., 2013, Vol. 31, no. 1, pp. 71-75.
89. Kobayashi E., Kishi H., Ozawa T., Hamana H., Nakagawa H., Jin A., Lin Z., Muraguchi A. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochemical and Biophysical Research Communications, 2014, Vol. 453, no. 4, pp. 798-803.
90. Kobayashi H., Dubois S., Sato N., Sabzevari H., Sakai Y., Waldmann T.A., Tagaya Y. Role of trans-cellular IL- 15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood, 2005, Vol. 105, no. 2, pp. 721-727.
91. Kobayashi M., Chiba A., Izawa H., Yanagida E., Okamoto M., Shimodaira S., Yonemitsu Y., Shibamoto Y., Suzuki N., Nagaya M., DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J. Ovarian. Res., 2014, Vol. 7, p. 48.
92. Kogler G., Enczmann J., Rocha V., Gluckman E., Wernet P. High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, -DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant, 2005, Vol. 36, no. 12, pp. 1033-1041.
93. Koido S., Homma S., Okamoto M., Takakura K., Mori M., Yoshizaki S., Tsukinaga S., Odahara S., Koyama S., Imazu H., Uchiyama K., Kajihara M., Arakawa H., Misawa T., Toyama Y., Yanagisawa S., Ikegami M., Kan S., Hayashi K., Komita H., Kamata Y., Ito M., Ishidao T., Yusa S., Shimodaira S., Gong J., Sugiyama H., Ohkusa T., Tajiri H. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res., 2014, Vol. 20, no. 16, pp. 4228-4239.
94. Koneru M., O’Cearbhaill R., Pendharkar S., Spriggs D.R., Brentjens R.J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med., 2015, Vol. 13, p. 102.
95. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T.H., Chang A., Coukos G., Liu R., Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 2009, Vol. 114, no. 6, pp. 1141-1149.
96. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., Gratama J.W., Stoter G., Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol., 2006, Vol. 24, no. 13, e20-2.
97. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther., 2013, Vol. 21, no. 4, pp. 904-912.
98. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med., 2005, Vol. 201, no. 2, pp. 233-240.
99. Lee H.W., Choi H.J., Ha S.J., Lee K.T., Kwon Y.G. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim. Biophys. Acta, 2013, Vol. 1835, no. 2, pp. 170-179.
100. Li J., Aipire A., Li J., Zhu H., Wang Y., Guo W., Li X., Yang J., Liu C. lambda-Carrageenan improves the antitumor effect of dendritic cellbased vaccine. Oncotarget, 2017, Vol. 8, no. 18, pp. 29996-30007
101. Li M., Wang B., Wu Z., Zhang J., Shi X., Cheng W., Han S. A novel recombinant protein of ephrinA1-PE38/ GM-CSF activate dendritic cells vaccine in rats with glioma. Tumour Biol., 2015, Vol. 36, no. 7, pp. 5497-5503.
102. Lim O., Jung M.Y., Hwang Y.K., Shin E.C. Present and future of allogeneic natural killer cell therapy. Front. Immunol., 2015, Vol. 6, p. 286.
103. Lim T.S., Chew V., Sieow J.L., Goh S., Yeong J.P., Soon A.L., Ricciardi-Castagnoli P. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology, 2016, Vol. 5, no. 3, e1085146.
104. Ljunggren H.G., Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today, 1990, Vol. 11, no. 7, pp. 237-244.
105. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol., 2007, Vol. 7, no. 5, pp. 329-339.
106. Lo A.S., Ma Q., Liu D.L., Junghans R.P. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res., 2010, Vol. 16, no. 10, pp. 2769-2780.
107. Long A.H., Haso W.M., Shern J.F., Wanhainen K.M., Murgai M., Ingaramo M., Smith J.P., Walker A.J., Kohler M.E., Venkateshwara V.R., Kaplan R.N., Patterson G.H., Fry T.J., Orentas R.J., Mackall C.L. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med., 2015, Vol. 21, no. 6, pp. 581-590.
108. Loo J.C., McGilveray I.J., Jordan N., Moffat J., Brien R. Dose-dependent pharmacokinetics of prednisone and prednisolone in man. Journal of Pharmacy and Pharmacology, 1978, Vol. 30, no. 11, p. 736.
109. Lopez-Guerrero J.A., Romero I., Poveda A. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin. J. Cancer, 2015, Vol. 34, no. 1, pp. 41-49.
110. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., Rossig C., Russell H.V., Diouf O., Liu E., Liu H., Wu M.F., Gee A.P., Mei Z., Rooney C.M., Heslop H.E., Brenner M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 2011, Vol. 118, no. 23, pp. 6050-6056.
111. Maier T., Tun-Kyi A., Tassis A., Jungius K.P., Burg G., Dummer R., Nestle F.O. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood, 2003, Vol. 102, no. 7, pp. 2338-2344.
112. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 2002, Vol. 23, no. 11, pp. 549-555.
113. Marcus A., Waks T., Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood, 2011, Vol. 118, no. 4, pp. 975-983.
114. Marks M.H., Rosen P.S. Adult orthodontics: periodontic and cosmetic enhancements. Compendium (Yardley, PA), 1991, Vol. 12, no. 8, pp. 584, 586, 588 passim.
115. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., Hwu P., Restifo N.P., Overwijk W.W., Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009, Vol. 31, no. 5, pp. 787-798.
116. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol., 2009, Vol. 27, pp. 451-483.
117. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, Vol. 371, no. 16, pp. 1507-1517.
118. McHugh R.S., Shevach E.M. The role of suppressor T cells in regulation of immune responses. Journal of Allergy and Clinical Immunology, 2002, Vol. 110, no. 5, pp. 693-702.
119. Michie C.A., McLean A., Alcock C., Beverley P.C. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature, 1992, Vol. 360, no. 6401, pp. 264-265.
120. Miller J.S. The biology of natural killer cells in cancer, infection, and pregnancy. Exp. Hematol., 2001, Vol. 29, no. 10, pp. 1157-1168.
121. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., Orchard P.J., Blazar B.R., Wagner J.E., Slungaard A., Weisdorf D.J., Okazaki I.J., McGlave P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, Vol. 105, no. 8, pp. 3051-3057.
122. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., Samanta M., Lakhal M., Gloss B., Danet-Desnoyers G., Campana D., Riley J.L., Grupp S.A., June C.H. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther., 2009, Vol. 17, no. 8, pp. 1453-1464.
123. Moretta A., Vitale M., Bottino C., Orengo A.M., Morelli L., Augugliaro R., Barbaresi M., Ciccone E., Moretta L. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med., 1993, Vol. 178, no. 2, pp. 597-604.
124. Morse M.A., Niedzwiecki D., Marshall J.L., Garrett C., Chang D.Z., Aklilu M., Crocenzi T.S., Cole D.J., Dessureault S., Hobeika A.C., Osada T., Onaitis M., Clary B.M., Hsu D., Devi G.R., Bulusu A., Annechiarico R.P., Chadaram V., Clay T.M., Lyerly H.K. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann. Surg., 2013, Vol. 258, no. 6, pp. 879-886.
125. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C.S., Kerstann K.W., Feigenbaum L., Chan C.C., Restifo N.P. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, Vol. 112, no. 2, pp. 362-373.
126. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, Vol. 29, no. 6, pp. 371-380.
127. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol., 2011, Vol. 11, no. 11, pp. 723-737.
128. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 1998, Vol. 4, no. 3, pp. 328-332.
129. Oelsner S., Friede M.E., Zhang C., Wagner J., Badura S., Bader P., Ullrich E., Ottmann O.G., Klingemann H., Tonn T., Wels W.S. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy, 2017, Vol. 19, no. 2, pp. 235-249.
130. Palmer D.H., Midgley R.S., Mirza N., Torr E.E., Ahmed F., Steele J.C., Steven N.M., Kerr D.J., Young L.S., Adams D.H. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology, 2009, Vol. 49, no. 1, pp. 124-132.
131. Pegram H.J., Lee J.C., Hayman E.G., Imperato G.H., Tedder T.F., Sadelain M., Brentjens R.J. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, 2012, Vol. 119, no. 18, pp. 4133-4141.
132. Pienta K.J., Machiels J.P., Schrijvers D., Alekseev B., Shkolnik M., Crabb S.J., Li S., Seetharam S., Puchalski T.A., Takimoto C., Elsayed Y., Dawkins F., de Bono J.S. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest. New Drugs, 2013, Vol. 31, no. 3, pp. 760-768.
133. Pluta K., Luce M.J., Bao L., Agha-Mohammadi S., Reiser J. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J. Gene Med., 2005, Vol. 7, no. 6, pp. 803-817.
134. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 2004, Vol. 4, no. 1, pp. 71-78.
135. Posey A.D., Jr., Schwab R.D., Boesteanu A.C., Steentoft C., Mandel U., Engels B., Stone J.D., Madsen T.D., Schreiber K., Haines K.M., Cogdill A.P., Chen T.J., Song D., Scholler J., Kranz D.M., Feldman M.D., Young R., Keith B., Schreiber H., Clausen H., Johnson L.A., June C.H. Engineered CAR T cells targeting the cancerassociated Tn-glycoform of the membrane Mucin MUC1 control adenocarcinoma. Immunity, 2016, Vol. 44, no. 6, pp. 1444-1454.
136. Pule M., Finney H., Lawson A. Artificial T-cell receptors. Cytotherapy, 2003, Vol. 5, no. 3, pp. 211-226.
137. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther., 2005, Vol. 12, no. 5, pp. 933-941.
138. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z., Yvon E., Weiss H.L., Liu H., Rooney C.M., Heslop H.E., Brenner M.K. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 2008, Vol. 14, no. 11, pp. 1264-1270.
139. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 2011, Vol. 475, no. 7355, pp. 222-225.
140. Qu H.Q., Zhou X.S., Zhou X.L., Wang J. Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac. J. Trop. Med., 2014, Vol. 7, no. 8, pp. 659-662.
141. Ren J., Zhang X., Liu X., Fang C., Jiang S., June C.H., Zhao Y. A versatile system for rapid multiplex genomeedited CAR T cell generation. Oncotarget, 2017, Vol. 8, no. 10, pp. 17002-17011.
142. Romanski A., Uherek C., Bug G., Seifried E., Klingemann H., Wels W.S., Ottmann O.G., Tonn T. CD19CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. Journal of Cellular and Molecular Medicine, 2016, Vol. 20, no. 7, pp. 1287-1294.
143. Rosenblatt J., Wu Z., Vasir B., Zarwan C., Stone R., Mills H., Friedman T., Konstantinopoulos P.A., Spentzos D., Ghebremichael M., Stevenson K., Neuberg D., Levine J.D., Joyce R., Tzachanis D., Boussiotis V., Kufe D., Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/ CD28. J. Immunother., 2010, Vol. 33, no. 2, pp. 155-166.
144. Rosenblatt J., Vasir B., Uhl L., Blotta S., Macnamara C., Somaiya P., Wu Z., Joyce R., Levine J.D., Dombagoda D., Yuan Y.E., Francoeur K., Fitzgerald D., Richardson P., Weller E., Anderson K., Kufe D., Munshi N., Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood, 2011, Vol. 117, no. 2, pp. 393-402.
145. Rossig C., Bollard C.M., Nuchtern J.G., Merchant D.A., Brenner M.K. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer, 2001, Vol. 94, no. 2, pp. 228-236.
146. Roybal K.T., Rupp L.J., Morsut L., Walker W.J., McNally K.A., Park J.S., Lim W.A. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 2016, Vol. 164, no. 4, pp. 770-779.
147. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, Vol. 295, no. 5562, pp. 2097-2100.
148. Ruggeri L., Mancusi A., Perruccio K., Burchielli E., Martelli M.F., Velardi A. Natural killer cell alloreactivity for leukemia therapy. J. Immunother., 2005, Vol. 28, no. 3, pp. 175-182.
149. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov., 2013, Vol. 3, no. 4, pp. 388-398.
150. Sahm C., Schonfeld K., Wels W.S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother., 2012, Vol. 61, no. 9, pp. 1451-1461.
151. Sakemura R., Terakura S., Watanabe K., Julamanee J., Takagi E., Miyao K., Koyama D., Goto T., Hanajiri R., Nishida T., Murata M., Kiyoi H. A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol. Res., 2016, Vol. 4, no. 8, pp. 658-668.
152. Samara P., Skopeliti M., Tsiatas M.L., Georgaki S., Gouloumis C., Voelter W., Dimopoulos A.M., Bamias A., Tsitsilonis O.E. A cytokine cocktail augments the efficacy of adoptive NK-92 cell therapy against mouse xenografts of human cancer. Anticancer Res., 2016, Vol. 36, no. 7, pp. 3373-3382.
153. Schirrmann T., Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk. Res., 2005, Vol. 29, no. 3, pp. 301-306.
154. Sheikh N.A., Petrylak D., Kantoff P.W., Dela Rosa C., Stewart F.P., Kuan L.Y., Whitmore J.B., Trager J.B., Poehlein C.H., Frohlich M.W., Urdal D.L. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother., 2013, Vol. 62, no. 1, pp. 137-147.
155. Smyth M.J., Cretney E., Kershaw M.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev., 2004, Vol. 202, pp. 275-293.
156. Sola C., Andre P., Lemmers C., Fuseri N., Bonnafous C., Blery M., Wagtmann N.R., Romagne F., Vivier E., Ugolini S. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc. Natl. Acad. Sci. USA, 2009, Vol. 106, no. 31, pp. 12879-12884.
157. Song D.G., Ye Q., Carpenito C., Poussin M., Wang L.P., Ji C., Figini M., June C.H., Coukos G., Powell D.J. Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res., 2011, Vol. 71, no. 13, pp. 4617-4627.
158. Song D.G., Ye Q., Poussin M., Harms G.M., Figini M., Powell D.J., Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood, 2012, Vol. 119, no. 3, pp. 696-706.
159. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., Sadelain M. T cellencoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med., 2007, Vol. 13, no. 12, pp. 1440-1449.
160. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 2001, Vol. 97, no. 1, pp. 192-197.
161. Sun J.B., Eriksson K., Li B.L., Lindblad M., Azem J., Holmgren J. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Clin. Immunol., 2004, Vol. 112, no. 1, pp. 35-44.
162. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med., 2009, Vol. 266, no. 2, pp. 154-181.
163. Svane I.M., Pedersen A.E., Johansen J.S., Johnsen H.E., Nielsen D., Kamby C., Ottesen S., Balslev E., Gaarsdal E., Nikolajsen K., Claesson M.H. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother., 2007, Vol. 56, no. 9, pp. 1485-1499.
164. Tada F., Abe M., Hirooka M., Ikeda Y., Hiasa Y., Lee Y., Jung N.C., Lee W.B., Lee H.S., Bae Y.S., Onji M. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int. J. Oncol., 2012, Vol. 41, no. 5, pp. 1601-1609.
165. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 2000, Vol. 356, no. 9232, pp. 802-807.
166. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., Iwakura Y., Yagita H., Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med., 2001, Vol. 7, no. 1, pp. 94-100.
167. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.G. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther., 1999, Vol. 10, no. 8, pp. 1359-1373.
168. Tammana S., Huang X., Wong M., Milone M.C., Ma L., Lefvine B.L., June C.H., Wagner J.E., Blazar B.R., Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther., 2010, Vol. 21, no. 1, pp. 75-86.
169. Tesone A.J., Rutkowski M.R., Brencicova E., Svoronos N., Perales-Puchalt A., Stephen T.L., Allegrezza M.J., Payne K.K., Nguyen J.M., Wickramasinghe J., Tchou J., Borowsky M.E., Rabinovich G.A., Kossenkov A.V., ConejoGarcia J.R. Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Rep., 2016, Vol. 14, no. 7, pp. 1774-1786.
170. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., Qian X., James S.E., Raubitschek A., Forman S.J., Gopal A.K., Pagel J.M., Lindgren C.G., Greenberg P.D., Riddell S.R., Press O.W. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20specific T cells. Blood, 2008, Vol. 112, no. 6, pp. 2261-2271.
171. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., Taidi B., Rajapaksa R., Caspar C.B., Okada C.Y., van Beckhoven A., Liles T.M., Engleman E.G., Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 2002, Vol. 99, no. 5, pp. 1517-1526.
172. Topfer K., Cartellieri M., Michen S., Wiedemuth R., Muller N., Lindemann D., Bachmann M., Fussel M., Schackert G., Temme A. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J. Immunol., 2015, Vol. 194, no. 7, pp. 3201-3212.
173. Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G. Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines. J. Biomed. Biotechnol., 2010, Vol. 2010, e904767. doi: 10.1155/2010/904767.
174. Vago L., Perna S.K., Zanussi M., Mazzi B., Barlassina C., Stanghellini M.T., Perrelli N.F., Cosentino C., Torri F., Angius A., Forno B., Casucci M., Bernardi M., Peccatori J., Corti C., Bondanza A., Ferrari M., Rossini S., Roncarolo M.G., Bordignon C., Bonini C., Ciceri F., Fleischhauer K. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med., 2009, Vol. 361, no. 5, pp. 478-488.
175. Valone F.H., Small E., MacKenzie M., Burch P., Lacy M., Peshwa M.V., Laus R. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J., 2001, Vol. 7, Suppl 2, pp. S53-61.
176. Vanbervliet B., Bendriss-Vermare N., Massacrier C., Homey B., de Bouteiller O., Briere F., Trinchieri G., Caux C. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med., 2003, Vol. 198, no. 5, pp. 823-830.
177. Vey N., Bourhis J.H., Boissel N., Bordessoule D., Prebet T., Charbonnier A., Etienne A., Andre P., Romagne F., Benson D., Dombret H., Olive D. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, Vol. 120, no. 22, pp. 4317-4323.
178. Vlieger M.D., Megens P., van der Sluys J. Recording pulsations in echo-encephalography. Medical and Biological Engineering, 1974, Vol. 12, no. 4, pp. 503-509.
179. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene, 2008, Vol. 27, no. 45, pp. 5932-5943.
180. Walker D.G., Laherty R., Tomlinson F.H., Chuah T., Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J. Clin. Neurosci., 2008, Vol. 15, no. 2, pp. 114-121.
181. Wang L., Ma N., Okamoto S., Amaishi Y., Sato E., Seo N., Mineno J., Takesako K., Kato T., Shiku H. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 2016, Vol. 5, no. 9, e1211218. doi: 10.1080/2162402X.2016.1211218.
182. Wang Q.S., Wang Y., Lv H.Y., Han Q.W., Fan H., Guo B., Wang L.L., Han W.D. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther., 2015, Vol. 23, no. 1, pp. 184-191.
183. Wang Y., Xu Z., Zhou F., Sun Y., Chen J., Li L., Jin H., Qian Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp. Hematol. Oncol., 2015, Vol. 4, p. 32.
184. Wei S.M., Pan H.L., Wang L., Yin G.L., Zhong K., Zhou Y., Yang S.J., Xin Z.L. Combination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice. Turk. J. Med. Sci., 2017, Vol. 47, no. 2, pp. 658-667.
185. Wei Y.C., Sticca R.P., Li J., Holmes L.M., Burgin K.E., Jakubchak S., Bouton-Verville H., Williamson J., Meyer K., Evans L., Martin J., Stephenson J.J., Trocha S., Smith S., Wagner T.E. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol. Rep., 2007, Vol. 18, no. 3, pp. 665-671.
186. Wilkie S., Picco G., Foster J., Davies D.M., Julien S., Cooper L., Arif S., Mather S.J., Taylor-Papadimitriou J., Burchell J.M., Maher J. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol., 2008, Vol. 180, no. 7, pp. 4901-4909.
187. Wilkie S., van Schalkwyk M.C., Hobbs S., Davies D.M., van der Stegen S.J., Pereira A.C., Burbridge S.E., Box C., Eccles S.A., Maher J. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol., 2012, Vol. 32, no. 5, pp. 1059-1070.
188. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., June C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and latestage ovarian cancer. Cancer Res., 2001, Vol. 61, no. 12, pp. 4766-4772.
189. Wu C.Y., Roybal K.T., Puchner E.M., Onuffer J., Lim W.A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 2015, Vol. 350, no. 6258, aab4077. doi: 10.1126/science.aab4077.
190. Yamanaka R., Homma J., Yajima N., Tsuchiya N., Sano M., Kobayashi T., Yoshida S., Abe T., Narita M., Takahashi M., Tanaka R. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer Res., 2005, Vol. 11, no. 11, pp. 4160-4167.
191. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA, 2002, Vol. 99, no. 25, pp. 16168-16173.
192. Yu J.S., Wheeler C.J., Zeltzer P.M., Ying H., Finger D.N., Lee P.K., Yong W.H., Incardona F., Thompson R.C., Riedinger M.S., Zhang W., Prins R.M., Black K.L. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res., 2001, Vol. 61, no. 3, pp. 842-847.
193. Yuan A., Hsiao Y.J., Chen H.Y., Chen H.W., Ho C.C., Chen Y.Y., Liu Y.C., Hong T.H., Yu S.L., Chen J.J., Yang P.C. Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci. Rep., 2015, Vol. 5, 14273. doi: 10.1038/srep14273
194. Yvon E.S., Burga R., Powell A., Cruz C.R., Fernandes R., Barese C., Nguyen T., Abdel-Baki M.S., Bollard C.M. Cord blood natural killer cells expressing a dominant negative TGF-beta receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy, 2017, Vol. 19, no. 3, pp. 408-418.
195. Zah E., Lin M.Y., Silva-Benedict A., Jensen M.C., Chen Y.Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res., 2016, Vol. 4, no. 6, pp. 498-508.
196. Zhang C., Burger M.C., Jennewein L., Genssler S., Schonfeld K., Zeiner P., Hattingen E., Harter P.N., Mittelbronn M., Tonn T., Steinbach J.P., Wels W.S. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J. Natl. Cancer. Inst., 2016, Vol. 108, no. 5.
197. Zhang G., Liu R., Zhu X., Wang L., Ma J., Han H., Wang X., Zhang G., He W., Wang W., Liu C., Li S., Sun M., Gao B. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunology and Cell Biology, 2013, Vol. 91, no. 10, pp. 615-624.
198. Zhang Y., Choksi S., Chen K., Pobezinskaya Y., Linnoila I., Liu Z.G. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res., 2013, Vol. 23, no. 7, pp. 898-914.
199. Zhou G., Levitsky H. Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clinical and Developmental Immunology, 2012, Vol. 2012, 124187. doi: 10.1155/2012/124187.
200. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., Storkus W.J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 1996, Vol. 183, no. 1, pp. 87-97.
Review
For citations:
Lezhnin Yu.N., Khristichenko A.Yu., Ratnikova N.M., Kravchenko Yu.E., Chumakov S.P. CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASES. Medical Immunology (Russia). 2018;20(3):313-340. (In Russ.) https://doi.org/10.15789/1563-0625-2018-3-313-340
Views:
1845
Email this article 